SiBone (NASDAQ:SIBN) CFO Sells $87,002.25 in Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 4,665 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $18.65, for a total transaction of $87,002.25. Following the transaction, the chief financial officer owned 251,895 shares in the company, valued at $4,697,841.75. The trade was a 1.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total transaction of $55,626.09.

SiBone Trading Down 2.2%

Shares of SIBN opened at $19.48 on Friday. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $21.89. The firm has a market cap of $863.92 million, a price-to-earnings ratio of -57.29 and a beta of 0.66. The firm has a 50 day moving average price of $17.40 and a 200-day moving average price of $15.30. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.06. The company had revenue of $56.01 million for the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. As a group, equities research analysts forecast that SiBone will post -0.4 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Weiss Ratings downgraded SiBone from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Truist Financial restated a “buy” rating and set a $23.00 price target (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. TD Cowen lifted their price target on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, UBS Group boosted their price objective on SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.17.

Institutional Trading of SiBone

Large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in SiBone in the 1st quarter worth $225,000. Goldman Sachs Group Inc. lifted its position in shares of SiBone by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after purchasing an additional 83,919 shares during the period. Jane Street Group LLC purchased a new stake in shares of SiBone in the 1st quarter worth about $1,818,000. Finally, Legal & General Group Plc boosted its stake in shares of SiBone by 16.1% during the 2nd quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock valued at $798,000 after purchasing an additional 5,888 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.